Assessment cycle 2024 Q3
Documents ratified in the 2024 Q3 assessment cycle, which ran from 1 July 2024 to 30 September 2024 and was ratified on 18 September 2024.
Documents ratified
-
Record of documents ratified in the 2024 Q3 assessment cycle.
18 Sep 2024 -
Consultation on the policy governing how the Institute cites evidence. The draft requires that every citation resolve to a retrievable source, that an identifier the…
05 Oct 2024 -
Consultation on the policy governing how the Institute corrects a published document and how versions are numbered, retained and linked. The draft retains every…
06 Sep 2024 -
Consultation on the draft monograph for AOD-9604, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Sep 2024 -
Consultation on the draft monograph for Gonadorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
08 Sep 2024 -
Consultation on the draft monograph for Hexarelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
27 Aug 2024 -
Consultation on the draft monograph for Larazotide acetate, which the assessment committee released for public comment before ratification. The draft grades the…
16 Oct 2024 -
Consultation on the draft monograph for Thymosin alpha-1, which the assessment committee released for public comment before ratification. The draft grades the compound's…
13 Nov 2024 -
Consultation on the draft of this network meta-analysis, which registers the question: Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an…
10 Oct 2024 -
Consultation on the draft of this analytical evidence review, which registers the question: How large is the discrepancy between labelled peptide mass and delivered…
01 Sep 2024 -
Consultation on the draft of this methodological review, which registers the question: What is known about the direction and magnitude of the difference between…
18 Oct 2024 -
Consultation on the draft of this intervention review, which registers the question: What is the effect of an amylin receptor agonist alone and in combination with a…
26 Sep 2024 -
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body…
High23 May 2025 -
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric…
Low17 Mar 2025 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
What is the evidence for thymic peptides in chronic viral hepatitis, sepsis and non-specific immune support?
Low17 Jun 2025 -
What in-use period can be supported for a reconstituted research peptide solution?
Moderate23 Jan 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Lixisenatide compared with the comparator used in its contributing trials on the anchor…
High01 Nov 2024 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Teduglutide compared with the comparator used in its…
Moderate28 Jun 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of CJC-1295 compared with the comparator used in…
Low12 Dec 2024 -
Synthesis: Maridebart cafraglutide in obesity and overweight in adults: effect on the anchor outcome
In the population defined for obesity and overweight in adults, what is the effect of Maridebart cafraglutide compared with the comparator used in its contributing…
Low13 Nov 2024 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the effect of Semaglutide compared with the comparator used in its…
Moderate14 Apr 2025 -
In the population defined for cognitive performance and neuroprotection, what is the effect of Semax compared with the comparator used in its contributing trials on the…
Very low26 Dec 2024 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Survodutide compared with its…
Moderate15 Jul 2025 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the incidence of adverse events leading to discontinuation with Thymosin alpha-1…
Moderate30 Mar 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with Thymosin beta-4 compared…
Low24 Jul 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High27 Nov 2024 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Moderate26 Jun 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared…
Low21 Jan 2025 -
In the population defined for cognitive performance and neuroprotection, what is the incidence of adverse events leading to discontinuation with Semax compared with its…
Very low11 Jan 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the incidence of adverse events leading to discontinuation with…
Moderate08 Dec 2024 -
In the population defined for obesity and overweight in adults, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High01 Aug 2025 -
In the population defined for obesity and overweight in adults, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate09 Nov 2024 -
Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.
21 Aug 2024 -
Chronic immune-mediated inflammation of the intestinal tract, or disorders of intestinal permeability including coeliac disease.
08 Jul 2024 -
GLP-1 receptor agonist, Fc-fusion protein. Receptor pharmacology is that of the selective GLP-1 class, delivered from a large fusion protein. Because the molecule is above the renal filtration…
High23 Sep 2025 -
Long-acting amylin analogue. Amylin receptor agonism at the area postrema promoting meal-related satiation, with a formulation and half-life supporting weekly dosing. The…
Low20 Apr 2025 -
Assessment of appearance, cake integrity and reconstitution behaviour
High13 Sep 2025 -
Custom-synthesis peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines with a custom-synthesis emphasis.
01 Mar 2025
page 1 of 2